Nucleus Genomics, a startup focused on personalized genetic testing, has raised $14 million in a Series A funding round. This funding will support the development of its AI-powered consumer health platform, which offers genetic risk assessments for over 800 health conditions. The company is recognized for its pioneering work in DNA sequencing and aims to enhance understanding of how DNA variants influence medication responses, a concern for nine out of ten individuals. The acquisition of Irish biotech Cambrean by Nucleus Genomics further strengthens its position in the genetic testing market.